{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:09:38Z","timestamp":1772791778014,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-026-04024-8","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:17:40Z","timestamp":1772781460000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Simultaneous quantification of lifitegrast and Rebamipide in hydrogel-based contact lenses using spectroscopic method"],"prefix":"10.1007","volume":"46","author":[{"given":"Yashkumar R.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ketan M.","family":"Ranch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunjan","family":"Bodiwala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harshilkumar","family":"Jani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Lalwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuradha","family":"Gajjar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay R.","family":"Chidrawar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudarshan","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"4024_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2020.108294","volume":"201","author":"VL Perez","year":"2020","unstructured":"Perez VL, Stern ME, Pflugfelder SC (2020) Inflammatory basis for dry eye disease flares. Exp Eye Res 201:108294. https:\/\/doi.org\/10.1016\/j.exer.2020.108294","journal-title":"Exp Eye Res"},{"key":"4024_CR2","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nichols KK, Akpek EK et al (2017) TFOS DEWS II definition and classification report. Ocul Surf 15:276\u2013283. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.008","journal-title":"Ocul Surf"},{"key":"4024_CR3","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.ophtha.2017.07.010","volume":"124","author":"SC Pflugfelder","year":"2017","unstructured":"Pflugfelder SC, de Paiva CS (2017) The pathophysiology of dry eye disease. Ophthalmology 124:S4\u2013S13. https:\/\/doi.org\/10.1016\/j.ophtha.2017.07.010","journal-title":"Ophthalmology"},{"key":"4024_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106206","author":"HB Mohamed","year":"2022","unstructured":"Mohamed HB, Abd El-Hamid BN, Fathalla D, Fouad EA (2022) Current trends in pharmaceutical treatment of dry eye disease: a review. Eur J Pharm Sci. https:\/\/doi.org\/10.1016\/j.ejps.2022.106206","journal-title":"Eur J Pharm Sci"},{"key":"4024_CR5","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3390\/ijms18071398","volume":"18","author":"X Zhang","year":"2017","unstructured":"Zhang X, Vimalin Jeyalatha M, Qu Y et al (2017) Dry eye management: targeting the ocular surface microenvironment. Int J Mol Sci 18:1398. https:\/\/doi.org\/10.3390\/ijms18071398","journal-title":"Int J Mol Sci"},{"key":"4024_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26178556","volume":"26","author":"J Jones","year":"2025","unstructured":"Jones J, Frenia K, Gelman J et al (2025) Translating biomarker discovery: from bench to bedside in dry eye disease. Int J Mol Sci 26:8556. https:\/\/doi.org\/10.3390\/ijms26178556","journal-title":"Int J Mol Sci"},{"key":"4024_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114582","author":"N Nagai","year":"2022","unstructured":"Nagai N, Otake H (2022) Novel drug delivery systems for the management of dry eye. Adv Drug Deliv Rev. https:\/\/doi.org\/10.1016\/j.addr.2022.114582","journal-title":"Adv Drug Deliv Rev"},{"key":"4024_CR8","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4103\/0976-500X.195920","volume":"7","author":"A Abidi","year":"2016","unstructured":"Abidi A, Shukla P, Ahmad A (2016) Lifitegrast: a novel drug for treatment of dry eye disease. J Pharmacol Pharmacother 7:194\u2013198. https:\/\/doi.org\/10.4103\/0976-500X.195920","journal-title":"J Pharmacol Pharmacother"},{"key":"4024_CR9","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S110557","volume":"10","author":"C Semba","year":"2016","unstructured":"Semba C, Gadek T (2016) Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease. Clin Ophthalmol 10:83. https:\/\/doi.org\/10.2147\/OPTH.S110557","journal-title":"Clin Ophthalmol"},{"key":"4024_CR10","doi-asserted-by":"publisher","DOI":"10.1177\/2515841419870366","author":"SL Haber","year":"2019","unstructured":"Haber SL, Benson V, Buckway CJ et al (2019) Lifitegrast: a novel drug for patients with dry eye disease. Ther Adv Ophthalmol. https:\/\/doi.org\/10.1177\/2515841419870366","journal-title":"Ther Adv Ophthalmol"},{"key":"4024_CR11","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.2147\/OPTH.S184776","volume":"12","author":"A Gonzalez","year":"2018","unstructured":"Gonzalez A (2018) Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort. Clin Ophthalmol 12:2079\u20132085. https:\/\/doi.org\/10.2147\/OPTH.S184776","journal-title":"Clin Ophthalmol"},{"key":"4024_CR12","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1080\/03007995.2016.1210107","volume":"32","author":"EJ Holland","year":"2016","unstructured":"Holland EJ, Whitley WO, Sall K et al (2016) Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials. Curr Med Res Opin 32:1759\u20131765. https:\/\/doi.org\/10.1080\/03007995.2016.1210107","journal-title":"Curr Med Res Opin"},{"key":"4024_CR13","doi-asserted-by":"publisher","first-page":"7155","DOI":"10.3390\/jcm12227155","volume":"12","author":"A Ballesteros-S\u00e1nchez","year":"2023","unstructured":"Ballesteros-S\u00e1nchez A, S\u00e1nchez-Gonz\u00e1lez MC, De-Hita-Cantalejo C et al (2023) The efficacy and safety of Rebamipide ophthalmic suspension (OPC-12759) in patients with dry eye disease: a systematic review of randomized controlled trials. J Clin Med 12:7155. https:\/\/doi.org\/10.3390\/jcm12227155","journal-title":"J Clin Med"},{"key":"4024_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/8145731","volume":"2019","author":"Y Sakane","year":"2019","unstructured":"Sakane Y, Yamaguchi M, Shiraishi A (2019) Retrospective observational study on Rebamipide ophthalmic suspension on quality of life of dry eye disease patients. J Ophthalmol 2019:1\u20138. https:\/\/doi.org\/10.1155\/2019\/8145731","journal-title":"J Ophthalmol"},{"key":"4024_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20164031","volume":"20","author":"C Simsek","year":"2019","unstructured":"Simsek C, Kojima T, Nakamura S et al (2019) The effects of Rebamipide 2% ophthalmic solution application on murine subbasal corneal nerves after environmental dry eye stress. Int J Mol Sci 20:4031. https:\/\/doi.org\/10.3390\/ijms20164031","journal-title":"Int J Mol Sci"},{"key":"4024_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-023-03004-1","volume":"23","author":"Y Eom","year":"2023","unstructured":"Eom Y, Chung SH, Chung T-Y et al (2023) Efficacy and safety of 1% and 2% Rebamipide clear solution in dry eye disease: a multicenter randomized trial. BMC Ophthalmol 23:343. https:\/\/doi.org\/10.1186\/s12886-023-03004-1","journal-title":"BMC Ophthalmol"},{"key":"4024_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-015-0040-0","volume":"15","author":"K Ueda","year":"2015","unstructured":"Ueda K, Matsumiya W, Otsuka K et al (2015) Effectiveness and relevant factors of 2% Rebamipide ophthalmic suspension treatment in dry eye. BMC Ophthalmol 15:58. https:\/\/doi.org\/10.1186\/s12886-015-0040-0","journal-title":"BMC Ophthalmol"},{"key":"4024_CR18","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.3109\/10717544.2016.1138342","volume":"23","author":"FA Maulvi","year":"2016","unstructured":"Maulvi FA, Soni TG, Shah DO (2016) A review on therapeutic contact lenses for ocular drug delivery. Drug Deliv 23:3017\u20133026. https:\/\/doi.org\/10.3109\/10717544.2016.1138342","journal-title":"Drug Deliv"},{"key":"4024_CR19","doi-asserted-by":"publisher","first-page":"994","DOI":"10.2174\/0115734129341673241106101546","volume":"20","author":"H Jani","year":"2025","unstructured":"Jani H, Ranch K, Lalwani R et al (2025) Sensitive HPLC method to support pre-formulation studies and to determine critical quality attributes of therapeutic contact lenses containing dorzolamide hydrochloride. Curr Pharm Anal 20:994\u20131004. https:\/\/doi.org\/10.2174\/0115734129341673241106101546","journal-title":"Curr Pharm Anal"},{"key":"4024_CR20","doi-asserted-by":"publisher","unstructured":"Choi SW, Kim J (2018) Therapeutic contact lenses with polymeric vehicles for ocular drug delivery: a review. Materials 11:1125. https:\/\/doi.org\/10.3390\/ma11071125","DOI":"10.3390\/ma11071125"},{"key":"4024_CR21","doi-asserted-by":"publisher","DOI":"10.2174\/97898152741651240101","volume-title":"Novel drug delivery systems (Part 2)","author":"AS Mundada","year":"2024","unstructured":"Mundada AS, Chaudhari A (2024) Novel drug delivery systems (Part 2). Bentham Science Publishers"},{"key":"4024_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.oftal.2019.07.009","volume":"95","author":"MA Holgado","year":"2020","unstructured":"Holgado MA, Anguiano-Dom\u00ednguez A, Mart\u00edn-Banderas L (2020) Lentes de contacto para vehiculizar principios activos: una prometedora herramienta terap\u00e9utica. Arch Soc Esp Oftalmol 95:24\u201333. https:\/\/doi.org\/10.1016\/j.oftal.2019.07.009","journal-title":"Arch Soc Esp Oftalmol"},{"key":"4024_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17081087","volume":"17","author":"HS Jani","year":"2025","unstructured":"Jani HS, Ranch K, Pandya R et al (2025) An update on novel drug delivery systems for the management of glaucoma. Pharmaceutics 17:1087. https:\/\/doi.org\/10.3390\/pharmaceutics17081087","journal-title":"Pharmaceutics"},{"key":"4024_CR24","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/09205063.2020.1712175","volume":"31","author":"X Zhang","year":"2020","unstructured":"Zhang X, Cao X, Qi P (2020) Therapeutic contact lenses for ophthalmic drug delivery: major challenges. J Biomater Sci Polym Ed 31:549\u2013560. https:\/\/doi.org\/10.1080\/09205063.2020.1712175","journal-title":"J Biomater Sci Polym Ed"},{"key":"4024_CR25","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.26420\/austinjanalpharmchem.2022.1140","volume":"9","author":"S Pannu","year":"2022","unstructured":"Pannu S, Bhatia R, Kumar B (2022) A validated method developed for estimation of Lifitegrast in bulk and pharmaceutical dosage form by UV\u2013spectrophotometer and RP-HPLC. Austin J Anal Pharm Chem. 9:1140. https:\/\/doi.org\/10.26420\/austinjanalpharmchem.2022.1140","journal-title":"Austin J Anal Pharm Chem."},{"key":"4024_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2024.116039","volume":"242","author":"M U\u011fur","year":"2024","unstructured":"U\u011fur M, Bellur Atici E, Ozkan SA (2024) A specific chiral HPLC method for lifitegrast and determination of enantiomeric impurity in drug substance, ophthalmic product and stressed samples. J Pharm Biomed Anal 242:116039. https:\/\/doi.org\/10.1016\/j.jpba.2024.116039","journal-title":"J Pharm Biomed Anal"},{"key":"4024_CR27","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1080\/22297928.2022.2159522","volume":"12","author":"A Kumar","year":"2022","unstructured":"Kumar A, Chalannavar RK (2022) Characterization of degradation products of lifitegrast by mass spectrometry: development and validation of a stability-indicating reversed phase HPLC method. Anal Chem Lett 12:730\u2013744. https:\/\/doi.org\/10.1080\/22297928.2022.2159522","journal-title":"Anal Chem Lett"},{"key":"4024_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/chir.23636","author":"JS Kandula","year":"2024","unstructured":"Kandula JS, Rayala VVSPK, Parmar K et al (2024) Enantioselective polar-organic mode high-performance liquid chromatographic separation of lifitegrast on immobilized polysaccharide stationary phase and its application to pH-dependent chiral interconversion studies. Chirality. https:\/\/doi.org\/10.1002\/chir.23636","journal-title":"Chirality"},{"key":"4024_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2023.123892","volume":"1229","author":"E Kim","year":"2023","unstructured":"Kim E, Jang E, Jung W et al (2023) Establishment of an LC-MS\/MS method for quantification of lifitegrast in rabbit plasma and ocular tissues and its application to pharmacokinetic study. J Chromatogr B 1229:123892. https:\/\/doi.org\/10.1016\/j.jchromb.2023.123892","journal-title":"J Chromatogr B"},{"issue":"3","key":"4024_CR30","first-page":"1270","volume":"3","author":"PK Srivastava","year":"2011","unstructured":"Srivastava PK, Roy A (2011) Development and validation of a new UV method for the analysis of Rebamipide. Int J Pharmtech Res 3(3):1270\u20131274","journal-title":"Int J Pharmtech Res"},{"key":"4024_CR31","doi-asserted-by":"publisher","DOI":"10.52711\/0974-360x.2024.00524","author":"S Karajgi","year":"2024","unstructured":"Karajgi S, Kulkarni RV, Potadar S et al (2024) Quantitative detection of Rebamipide by zero order UV-spectrophotometry using dimethyl formamide solvent system. Res J Pharm Technol. https:\/\/doi.org\/10.52711\/0974-360x.2024.00524","journal-title":"Res J Pharm Technol"},{"key":"4024_CR32","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/jaoacint\/qsab099","volume":"105","author":"MA Alqarni","year":"2022","unstructured":"Alqarni MA, Moatamed RS, Naguib IA et al (2022) Development and validation of four spectrophotometric methods for assay of rebamipide and its impurity: application to tablet dosage form. J AOAC Int 105:299\u2013308. https:\/\/doi.org\/10.1093\/jaoacint\/qsab099","journal-title":"J AOAC Int"},{"key":"4024_CR33","doi-asserted-by":"publisher","first-page":"0","DOI":"10.21608\/aijpms.2023.163295.1171","volume":"0","author":"O Abdallah","year":"2023","unstructured":"Abdallah O, Mohamed T, Hendawy H, Elomda H (2023) Voltammetric determination of Rebamipide in the presence of its degradant in bulk, pharmaceutical preparation, and biological fluids. Azhar Int J Pharm Med Sci 0:0\u20130. https:\/\/doi.org\/10.21608\/aijpms.2023.163295.1171","journal-title":"Azhar Int J Pharm Med Sci"},{"key":"4024_CR34","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3797\/scipharm.1011-06","volume":"79","author":"S Sonawane","year":"2011","unstructured":"Sonawane S, Gide P (2011) Optimization of forced degradation using experimental design and development of a stability-indicating liquid chromatographic assay method for rebamipide in bulk and tablet dosage form. Sci Pharm 79:85\u201396. https:\/\/doi.org\/10.3797\/scipharm.1011-06","journal-title":"Sci Pharm"},{"key":"4024_CR35","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1081\/JLC-120038778","volume":"27","author":"MK Jeoung","year":"2004","unstructured":"Jeoung MK, Kim CS, Kim NH et al (2004) Determination of rebamipide in human plasma by HPLC. J Liq Chromatogr Relat Technol 27:1925\u20131935. https:\/\/doi.org\/10.1081\/JLC-120038778","journal-title":"J Liq Chromatogr Relat Technol"},{"key":"4024_CR36","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.56061","author":"D Kako","year":"2024","unstructured":"Kako D, Ghareeb MM, Al-Lami MS (2024) High-performance liquid chromatography (HPLC) method validation for identifying and quantifying Rebamipide in ethosomes. Cureus. https:\/\/doi.org\/10.7759\/cureus.56061","journal-title":"Cureus"},{"key":"4024_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2021.112096","author":"FA Maulvi","year":"2021","unstructured":"Maulvi FA, Soni PD, Patel PJ et al (2021) Controlled bimatoprost release from graphene oxide laden contact lenses: in vitro and in vivo studies. Colloids Surf B Biointerfaces. https:\/\/doi.org\/10.1016\/j.colsurfb.2021.112096","journal-title":"Colloids Surf B Biointerfaces"},{"key":"4024_CR38","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/17435889.2025.2463867","volume":"20","author":"J Dave","year":"2025","unstructured":"Dave J, Jani H, Patel Y et al (2025) Polyol-modified deformable liposomes fortified contact lenses for improved ocular permeability. Nanomedicine 20:649\u2013662. https:\/\/doi.org\/10.1080\/17435889.2025.2463867","journal-title":"Nanomedicine"},{"key":"4024_CR39","doi-asserted-by":"publisher","first-page":"16110","DOI":"10.1039\/D5RA01046B","volume":"15","author":"K Panchal","year":"2025","unstructured":"Panchal K, Patel Y, Jani H et al (2025) Indomethacin-incorporated microemulsion-laden contact lenses for improved ocular drug delivery and therapeutic efficacy. RSC Adv 15:16110\u201316124. https:\/\/doi.org\/10.1039\/D5RA01046B","journal-title":"RSC Adv"},{"key":"4024_CR40","doi-asserted-by":"publisher","DOI":"10.1080\/09205063.2024.2391233","author":"D Chawnani","year":"2024","unstructured":"Chawnani D, Ranch K, Patel C et al (2024) Design and optimization of acetazolamide nanoparticle-laden contact lens using statistical experimental design for controlled ocular drug delivery. J Biomater Sci Polym Ed. https:\/\/doi.org\/10.1080\/09205063.2024.2391233","journal-title":"J Biomater Sci Polym Ed"},{"key":"4024_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17121515","volume":"17","author":"K Ranch","year":"2025","unstructured":"Ranch K, Patel Y, Acharya E et al (2025) Enhanced ocular delivery of epalrestat using nanostructured lipid carrier laden soft contact lens. Pharmaceutics 17:1515. https:\/\/doi.org\/10.3390\/pharmaceutics17121515","journal-title":"Pharmaceutics"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04024-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-026-04024-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04024-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:17:41Z","timestamp":1772781461000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-026-04024-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4024"],"URL":"https:\/\/doi.org\/10.1007\/s10792-026-04024-8","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) declare no conflict of interest, financial or otherwise.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"147"}}